14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CNTB vs CLYM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (45.7/100 HOLD vs. 41.0/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. CNTB trades at $0.59 (0.8x Forward P/E, -2384.5% operating margin) versus CLYM at $9.64 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (45.7/100 HOLD vs. CNTB 41.0/100 SELL) and 1.52β · 112% Vol risk profile, whereas CNTB leads top-line expansion (+5666.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CNTB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNTB vs CLYM. Trailing 12-month operating profitability (CNTB -2384.5% vs CLYM 0.0%) and valuation multiples (CNTB 0.8x vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $608.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CNTB vs CLYM Key Questions & Quantitative Answers
As of Nov 17, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Connect Biopharma Holdings Limited (CNTB) on higher Unified Composite conviction (45.7/100 HOLD vs. 41.0/100 SELL) after splitting the core matrix 5–4 (led by Profitability & Quality), while CNTB wins 4–1 across the 6-pillar growth and valuation breakdown. CNTB trades at $0.59 (0.8x Forward P/E, -2384.5% operating margin) versus CLYM at $9.64 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (45.7/100 HOLD vs. CNTB 41.0/100 SELL) and 1.52β · 112% Vol risk profile, whereas CNTB leads top-line expansion (+5666.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CNTB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.6); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CNTB leads the Growth & Scale pillar: CNTB posts +5666.7% YoY revenue growth and +0.0% YoY earnings growth on $3.0M TTM revenue (100.0% gross margin, -2384.5% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CNTB generates $3.0M in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, CNTB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.
CNTB screens cheaper on headline valuation multiples. CNTB trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 5.5x EV/Revenue (unreported FCF margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNTB (-140.5% ROE) versus CLYM (-29.3% ROE) capital efficiency.
In options market volatility and institutional positioning, CNTB carries 397.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 68% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 112% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.